GBMA
Returning to the fray
Leading health bureaucrat returns to head up generics and biosimilars peak body Jane Halton, former Secretary of the Department of Health has been appointed as the inaugural independent chair of …
Stakeholders reject Interim Report options
Members of the Medicines Partnership of Australia have banded together to raise concerns about the future stability of pharmacy The stakeholders, which include the Guild, PSA, ASMI, Generic and Biosimilar …
Therapeutic goods streamlining welcomed
Australia can streamline the regulation of therapeutic goods by removing duplicative and inefficient processes without undermining the safety and quality of medicines, the GBMA says following the Government’s response to …
Absence of more PBS reform honours commitment
The 2016 Budget confirms the significant ongoing PBS savings provided by generic medicines, and signals the government’s intent to streamline medicine regulation processes, says GBMA. The absence of further PBS …
Evergreening delays access: GBMA
Evergreening strategies delay market entry for generic medicines to the detriment of the Australian community and there is a lack of evidence to support extending market exclusivity for pharmaceuticals, according …
Delistings, shortages looming as discount well runs dry
Pharmacy is set to see more delistings and stock shortages this year as a result of simplified price disclosure, GBMA president Belinda Wood warned over the weekend. Presenting at APP2016, …
GBMA welcomes PBS listing of infliximab
The inclusion of the first monoclonal antibody biosimilar on the PBS will deliver immediate savings to the Federal Government; however the full potential of this and other biosimilar medicines relies …
GBMA welcomes the ‘a’ flagging of biosimilar infliximab
The Generic and Biosimilar Medicines Association has welcomes the recommendation by the PBAC to list biosimilar infliximab (Inflectra) on the PBS and to recommend the marking as equivalent, also known …